Interested in reading more about the IPN? Join our newsletter! We publish each Spring and Fall. We share about our research of course, but you can also get an inside look at what we're all about here at the #UCDavisIPN. Sign up here:

IPN collaborator Dr. Uri Manor at @ucsandiego.bsky.social reveals that #psychedelics as well as non-hallucinogenic analogues developed at the #UCDavisIPN can grow new synapses in the cochlea of mice which could open new horizons for treating age-related hearing loss.

New in @jama.com: A phase 2b trial of an oral LSD formulation (MM120) found that 100 µg and 200 µg doses significantly reduced anxiety symptoms in adults with generalized anxiety disorder. Results support 100 µg as the optimal dose for future trials.

Reunion Neuroscience has achieved positive topline results from the Phase 2 trial of RE104, a synthetic #psychedelic, in postpartum depression. This marks an exciting milestone for their mission. Remarkably, 71% of patients experienced remission of symptoms within 7 days.

On @npr.org’s The Sunday Story, IPN Director, @deolsonlab.bsky.social explains how #psychedelics may treat depression by promoting brain plasticity and why he’s working to engineer out the trip. 🎧 Hear more on the psychedelic renaissance and where science is headed:

Greg Watry of @ucdlands.bsky.social wrote a wonderful article about the #UCDavisIPN's @natureportfolio.nature.com most recent Neuroscience publication. Find out why our associate director, John A. Gray said, "Science is full of surprises." Read the article here: www.ucdavis.edu/news/psyched...

The field of psychedelic science is finally closer to an answer on how non-hallucinogenic psychedelic analogues induce neuroplasticity.  Read the new publication from the #UCDavisIPN in @natureportfolio.nature.com Neuroscience about how the team uncovered this using TBG, lasers, and genetic tools.

#UCDavisIPN Director @deolsonlab.bsky.social spoke with Lisa Wexler from the Voice of Connecticut about JRT, a non-hallucinogenic #psychedelic analogue with potential to treat schizophrenia. 🔗 Listen to David's segment on The Lisa Wexler Show here or anywhere you get your podcasts:

A team led by @zenbrainest.bsky.social and colleagues screened 41 classical #psychedelics across 318 human receptors. The result? A sweeping map of psychedelic polypharmacology that includes broad activity at serotonin, dopamine, and adrenergic receptors. 🔗 Read the full study:

Big news in #psychedelic science: Compass Pathways' proprietary psilocybin formulation is the first-ever classic psychedelic in a Phase 3 trial. It showed a significant reduction in depression symptoms compared to placebo. We’re very excited to see the data once published! Read the press release:

#UCDavisIPN Affiliate @sadeghlab.bsky.social co-authored a new @natureportfolio.nature.com paper revealing how maternal exposure to 5-HT2C agonists can cause the choroid plexus to secrete proteins into cerebrospinal fluid, affecting fetal brain development and behavior into adulthood. Read more:

Meet us at the Davis Public Library in Davis on May 29th for IPN Affiliate @manvir.bsky.social's author talk on "Shamanism: The Timeless Religion." Register for the event, hosted by the Avid Reader, using the link below. Where: 315 E. 14th Street, Davis, CA 95616 Time: 6:30PM #shamanism #UCDavisIPN

Now available: Shamanism: The Timeless Religion written by IPN Affiliate @manvir.bsky.social. Manvir's work cuts through myths and binaries, exploring the deeper meaning behind our fascination with shamanism and ancient ways of knowing. Order your copy now: #UCDavisIPN #shamanism

IPN Affiliate @manvir.bsky.social's new book "Shamanism: The Timeless Religion" releases May 20th. The book is a provocative journey through history, belief, and the incredible diversity of human spiritual and healing practices.

Thanks to NIH Research Matters team for recognizing the #UCDavisIPN's work on JRT. This work brings us closer to creating effective and practical treatments for patients.

Fascinating read by IPN affiliate @manvir.bsky.social in @theguardian.com on how stories about “ancient” psychedelic use are often shaped by what tourists want to hear, not necessarily what’s true. This is a must-read for anyone thinking about tradition, authenticity, and modern #psychedelics.

Check out this write-up on JRT, an LSD analogue created at the #UCDavisIPN published last week in @pnas.org. Thanks to BBRF for highlighting our research on how swapping just two atoms could change how schizophrenia is treated. Read more about our latest study here:

Thank you, Greg Watry, for this write-up on JRT, our non-hallucinogenic LSD analog from the #UCDavisIPN. This compound has the potential to treat patients affected by schizophrenia! @ucdavismedschool.bsky.social @ucdlands.bsky.social @ucdaviscns.bsky.social

The #UCDavisIPN's latest article in @pnas.org is out now. By transposing just 2 atoms in LSD, we synthesized JRT, a non-hallucinogenic analogue. Read about this and how the compound could be used as a potential treatment for schizophrenia here: www.pnas.org/doi/epub/10....

It’s #UCDavisGiveDay! Your support powers breakthroughs in mental health treatment — science that’s safe, scalable, and made to reach the people who need it most. Donate here: giveto.ucdavis.edu/campaigns/49... #EveryAggieCounts #UCDHstrong

Check out IPN Director @deolsonlab.bsky.social on NPR's Short Wave podcast. Part 1 gives an introduction to the breadth of psychedelic research and is out now. Stay tuned for part 3, where David discusses IPN research in more detail. Listen wherever you get your podcasts or at this link:

@alexkwan.bsky.social's team found that activation of 5-HT2A receptors on pyramidal tract neurons was key for psilocybin's effects on both structural neuroplasticity and antidepressant-like effects. Read about how this gets us closer to developing next-gen psychedelic-based therapeutics:

#UCDavisGiveDay is an annual fundraiser to support initiatives at UC Davis. This year, the IPN hopes to raise money to cover operational expenses and exciting new research. Your gift helps fuel our mission to explore groundbreaking treatments for mental health.

We are 10 days away from our ninth annual Give Day! As always, the goal of Give Day is to bring our community together by sharing, following or financially supporting programs that have made an impact on the lives of our alumni, students, UC Davis Health patients and veterinary clients.

Our research is essential to solving everyday challenges. From improving public health to addressing natural disaster risks, @ucdavis.bsky.social's "From Labs to Lives" series showcases how federal funding supports these impactful projects -- and what could be at risk with budget cuts.

Creating ethically AND scientifically sound clinical trials for psychedelic research is tricky - how do we blind participants when the hallucinogenic effects are all too noticeable? This article gives a few good examples:

Our team's synthesis of ibogaine reduced the number of steps from 9–15 down to just 7 and boosted total yield from 0.14–4.61% to an impressive 10–14%! This more efficient and cost-effective approach could open new doors for ibogaine research. Read more about this study here:

Vote for the #UCDavisIPN in the first round of @statnews.com's #STATMadness here: www.statnews.com/feature/stat.... Please help us show the world we're the best in biomedical research this year!

Register to attend the 25th annual Miller Symposium hosted by the UCD Dept. of Chemistry! Don't miss the chance to listen to the distinguished speakers, including Nobel Laureates @doudna-lab.bsky.social & @francesarnold.bsky.social Click here to register and see the full lineup: lnkd.in/dpPHAW2

Our work at the #UCDavisIPN is featured in a @natureportfolio.nature.com news article by @alexkwan.bsky.social! Read about how we've begun to uncover whether the "trip" is necessary for the anti-anxiety effects of #psychedelics. Read the article here:

Register today for the Bay Area #Psychedelic Science Symposium organized by former IPN trainee Lindsay Cameron. This symposium is a scientific event designed for academic researchers, clinicians, biotech professionals, and other experts in the field to collaborate and share ideas across disciplines.

The latest IPN research in @natureportfolio.nature.com details the total synthesis of ibogaine. The synthetic strategy created by a team led by IPN Director @deolsonlab.bsky.social enabled the synthesis of several ibogaine analogues with interesting biological properties. You can read the paper here

Hello World! The UC Davis Institute for Psychedelics and Neurotherapeutics has joined BlueSky. Follow us if you'd like to read about our latest research, events, and more. #psychedelics #mentalhealth #neuroscience #UCDavisIPN